After melanoma removal: margins, sentinel nodes and the next plan

A melanoma diagnosis in the pathology report can raise new questions after a skin lesion has been removed, even when the wound is healing. The initial procedure established the diagnosis, but the next plan depends on the tumour’s characteristics and what was done. A useful consultation connects the pathological findings with the decisions that now need to be made.

Obtain the complete report

Relevant findings include Breslow thickness, ulceration, margins and other reported characteristics. Thickness in millimetres is different from the diameter of a lesion on the skin’s surface. If the specimen was incomplete or transected at its base, interpretation may be limited. Ask the specialist which findings are established and which require clarification.

Add the procedure record with its date and exact location, the original lesion description and any photographs the clinician considers useful and that the patient agrees to share. Medical images do not need to be made public to obtain a consultation. Also record previous melanomas and other significant cancer history.

Why a wider excision may be discussed

Melanoma treatment often includes a wider local excision around the original site. Its extent is determined by the pathology and anatomy. A report of clear margins after diagnostic removal does not always establish that the required local treatment is complete. NCI describes wide local excision as an important surgical approach to melanoma. NCI: Melanoma Treatment.

Ask which finding supports the next operation, how the wound would be closed and whether reconstructive expertise may be needed. Excision width should not be selected independently from an online table. It belongs within an individual plan that relates the diagnosis to the operation being proposed.

Understand the question behind sentinel-node assessment

Sentinel nodes lie on one of the first lymph drainage routes from the original tumour. Their examination looks for microscopic spread that may not be visible on routine imaging. This is a staging question; recommending the procedure does not mean the clinician has already confirmed node involvement. Not everyone with melanoma needs it. The original tumour features and whether the finding would change subsequent care are part of the decision.

A negative finding means no cancer cells were identified in the examined material; it does not replace all other follow-up. A positive regional node changes the assessment, but is not automatically distant metastatic disease. The clinician should explain the resulting stage using the whole picture rather than the word positive alone.

Sentinel node assessment differs from removing every node in the region. Even with a positive result, the next steps may include ultrasound surveillance instead of immediate additional surgery for suitable patients. NCI describes this possibility in its melanoma treatment information; the clinical team determines whether it applies. It is not a reason to skip agreed investigations independently.

Before the procedure, clarify how it fits with the wider local excision, when the final result is expected and who will discuss it with you. The report should state how many nodes were examined and the detailed finding rather than leaving you with a short informal message.

Ask whether imaging or additional medicine is justified

The extent of further investigations and the need for additional treatment depend on the established stage and individual circumstances. A melanoma diagnosis does not mean that everyone needs the same set of PET-CT, MRI and laboratory tests. Ask which clinical question each proposed investigation is intended to answer.

If drug treatment after surgery is discussed, clarify the risk it aims to reduce, expected benefit and possible side effects. Additional tumour findings may be relevant to that decision. A new medicine’s name is not adequate justification without a connection to the stage and indication. Conversely, absence of a drug proposal does not mean follow-up has been omitted if local treatment and risk assessment support another approach.

Prepare the next consultation

If pathology is uncertain, arrange review of slides or blocks while retaining the original report. For an oncology second opinion, frame three focused questions: is local treatment complete, is additional nodal assessment appropriate and what follow-up is recommended?

If care in Turkey is being considered, identify who will perform skin examinations and receive later results at home. The absence of a visible lesion after removal does not eliminate the need for agreed follow-up. That programme should nevertheless reflect the individual’s risk rather than become the largest possible collection of tests without an explained purpose. A clear written conclusion helps both teams work from the same understanding.